Alvotech, a powerful new player in the field of biopharmaceuticals, and Finesse Solutions, Inc. (Finesse) have entered into a partnership that will provide Alvotech with world-class, scalable, flexible and cost-efficient manufacturing and laboratory technology through the Finesse turnkey SmartFactory GMP manufacturing platform suite.
SmartFactory is a single-use cGMP bio-manufacturing capacity, which will allow Alvotech to rapidly expand its biosimilars business. Finesse’s customers will benefit from unprecedented access to Alvogen’s commercial, FDA approved, biomanufacturing facility.
“This partnership allows us to leverage Finesse’s single-use bio-manufacturing automation platform, combining best-of-breed bio-process equipment from upstream through downstream. This strategic relationship provides us with much-needed additional manufacturing capacity and scale-up capabilities which will allow us to expedite our ambitions to become a global leader in the high-growth biopharmaceutical industry. The first manufacturing suite will be in place by the end of 2015,” said Dr Andreas Herrmann, CEO of Alvotech.